Health Care Knowledge

Daclatasvir is approved for the treatment of adult patients with hepatitis C, an infectious disease that specifically affects the liver, caused by HCV (Hepatitis C Virus).  This medication works in order to stop the multiplication of hepatitis C virus. It also stops infecting new cells. This helps in reducing the amount of hepatitis C virus in the body and eliminates the virus from the blood over a period of time.  Daclatasvir is prescribed to be used along with other medications against hepatitis C infection and must never be used by itself.  Dosage and Administration: The medication daclatasvir always should be taken exactly as your healthcare professional has instructed you. The recommended dose is daclatasvir 60 mg once daily. Swallow the tablet whole. Do not crush/chew the tablet as it has a bit of an unpleasant taste. Daclatasvir may be taken either with or without a meal.  Certain other drugs may be responsible for interacting with daclatasvir, affecting the levels of daclata

Methotrexate is used in order to treat gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole.  In acute lymphocytic leukemia, methotrexate is recommended in the prophylaxis of the meningeal leukemia and approved to be used in the maintenance therapy along with other chemotherapeutic agents.  The methotrexate injection is also used in the treatment of meningeal leukemia.  Methotrexate is approved to be used alone or together with other anticancer agents in order to treat breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell sorts.  Methotrexate is also approved to be used together with other chemotherapeutic agents in order to treat advanced stage non-Hodgkin’s lymphomas.  Methotrexate in high doses followed by leucovorin rescue along with the certain other chemotherapeutic agents is useful in the prolonging relapse-free survival in patients with non-

Gemcitabine (Gemzar) falls under the nucleoside analog family of medication, acts in order to block the creation of new DNA, which results in the death of cells. Foremost, during the early 1980s it was synthesized in Larry Hertel's lab at Eli Lilly and Company. Gemcitabine was intended as an antiviral medication, but preclinical testing demonstrated that it destroyed leukemia cells in vitro. In the early 1990s this medication was studied in the clinical trials. The trial of pancreatic cancer found that this agent increased the 1 year survival time significantly. In the year of 1995, Gemcitabine's approval in the UK took place and in the year of 1996 it was approved by the Food and Drug Administration in order to treat pancreatic cancers.  In the year of 1998, gemcitabine 200 mg received Food and Drug Administration approval in order to treat non-small cell lung cancer and in the year of 2004 it was approved for treating the metastatic breast cancer. In the year of 2008, Europe

Bortezomib (Velcade, specifically is an anti cancer agent, falls under the class of drugs known as proteasome inhibitors. It acts in order to inhibit the proteasomes, cellular complexes that are involved in breaking down the proteins.  In the month of May, 2003, the Food and Drug Administration approved bortezomib for injection in order to treat RRMM ( Relapsed and Refractory Multiple Myeloma ).  In the month of October, 2007, the Food and Drug Administration expanded Bortezomib for injection labels in order to treat patients with multiple myeloma.  In the month of June, 2008, the Food and Drug Administration approved Bortezomib for injection in order to treat patients with the previously untreated MM (Multiple Myeloma).  In the month of January, 2010, the Food and Drug Administration approved the addition of sustained overall survival benefit to the label for Bortezomib in order to treat patients with previously untreated MM (Multiple Myeloma).  In the month of January, 2012, the Food